Elevated markers of endothelial dysfunction predict type 2 diabetes mellitus in middle-aged men and women from the general population

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 26, Issue 2, 2006, Pages 398-405

  Thorand, Barbara ^a   Baumert, Jens ^a   Chambless, Lloyd ^b   Meisinger, Christa ^a   Kolb, Hubert ^c   Döring, Angela ^a   Löwel, Hannelore ^a   Koenig, Wolfgang ^d  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Adhesion molecules; Endothelial dysfunction; Type 2 diabetes; Von Willebrand factor

Indexed keywords

CELL MARKER; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; SOLUBLE E SELECTIN; SOLUBLE INTERCELLULAR ADHESION MOLECULE 1; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; BIOLOGICAL MARKER; C REACTIVE PROTEIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; ENDOTHELIAL DYSFUNCTION; FEMALE; HAZARD ASSESSMENT; HUMAN; HUMAN CELL; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; ATHEROSCLEROSIS; BLOOD; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PREDICTION AND FORECASTING; SOLUBILITY; VASCULAR ENDOTHELIUM;

ADULT; AGED; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; E-SELECTIN; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INCIDENCE; INTERCELLULAR ADHESION MOLECULE-1; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SOLUBILITY; VON WILLEBRAND FACTOR;

EID: 33644859602     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000198392.05307.aa     Document Type: Article

References (40)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
2. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999;340:115-126.
3. Pinkney JH, Stehouwer CDA, Coppack SW, Yudkin JS. Endothelial dysfunction: cause of the insulin resistance syndrome. Diabetes. 1997;46Suppl. 2:S9-S13.
4. Caballero AE. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes Res. 2003;11:1278-1289.
5. Blann A, Seigneur M. Soluble markers of endothelial cell function. Clin Hemorheol Microcirc. 1997;17:3-11.
6. Blann AD, Lip GY. Endothelial integrity, soluble adhesion molecules and platelet markers in type 1 diabetes mellitus. Diabet Med. 1998;15:634-642.
7. Conlan MG, Folsom AR, Finch A, Davis CE, Sorlie P, Marcucci G, Wu KK. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost. 1993;70:380-385.
8. Chen JW, Gall MA, Deckert M, Jensen JS, Parving HH. Increased serum concentration of von Willebrand factor in non-insulin dependent diabetic patients with and without diabetic nephropathy. BMJ. 1995;311:1405-1406.
9. Heywood DM, Mansfield MW, Grant PJ. Levels of von Willebrand factor, insulin resistance syndrome, and a common vWF gene polymorphism in non-insulin-dependent (type 2) diabetes mellitus. Diabet Med. 1996;13:720-725.
10. Galajda P, Martinka E, Mokan M, Kubisz P. Endothelial markers in diabetes mellitus. Thromb Res. 1997;85:63-65.
11. Albertini J-P, Valensi P, Lormeau B, Aurousseau M-H, Ferrière F, Attali J-R, Gattegno L. Elevated concentrations of soluble E-selectin and vascular cell adhesion molecule-1 in NIDDM. Diabetes Care. 1998;21:1008-1013.
12. Caballero AE, Arora S, Saouaf R, Lim SC, Smakowski P, Park JY, King GL, Logerfo FW, Horton ES, Veves A. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes. 1999;48:1856-1862.
13. Duncan BB, Schmidt MI, Offenbacher S, Wu KK, Savage PJ, Heiss G. Factor VIII and other hemostasis variables are related to incident diabetes in adults. The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care. 1999;22:767-772.
14. Krakoff J, Funahashi T, Stehouwer CDA, Schalkwijk CG, Tanaka S, Matsuzawa Y, Kobes S, Tataranni PA, Hanson RL, Knowler WC, Lindsay RS. Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care. 2003;26:1745-1751.
15. Meigs JB, Hu FB, Rifai N, Manson JE. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA. 2004;291:1978-1986.
16. WHO MONICA Project Principal Investigators (prepared by H.Tunstall-Pedoe). The World Health Organization MONICA Project (Monitoring of Trends and Determinants in Cardiovascular Disease): A major international collaboration. J Clin Epidemiol. 1988;34:105-114.
17. Prentice RL. A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika. 1986;73:1-11.
18. Hense HW, Filipiak B, Döring A, Stieber J, Liese A, Keil U. Ten-year trends of cardiovascular risk factors in the MONICA Augsburg Region in Southern Germany. Results from the 1984/85, 1989/90 and 1994/1995 surveys. CVD Prevention. 1998;1:318-327.
19. Schaeffler V, Döring A, Winkler G, Keil U. Trends in food consumption in a south German population from 1984/85 to 1989/90: results from the WHO MONICA project Augsburg. Ann Nutr Metab. 1996;40:129-136.
20. Meisinger C, Thorand B, Schneider A, Stieber J, Döring A, Löwel H. Sex differences in risk factors for incident type 2 diabetes mellitus - The MONICA Augsburg cohort study. Arch Intern Med. 2002;162:82-89.
21. Hutchinson WL, Koenig W, Fröhlich M, Sund M, Lowe GD, Pepys MB. Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. Clin Chem. 2000;46:934-938.
22. Khuseyinova N, Imhof A, Trischler G, Rothenbacher D, Hutchinson WL, Pepys MB, Koenig W. Determination of C-reactive protein: comparison of three high-sensitivity immunoassays. Clin Chem. 2003;49:1691-1695.
23. SAS Institute Inc. SAS/STAT User's Guide, Version 8. Cary, NC: SAS Institute Inc; 1999.
24. SAS Institute Inc. SAS/STAT User's Guide, Version 9.1. Cary, NC: SAS Institute Inc; 2004.
25. Barlow WE. Robust variance estimation for the case-cohort design. Biometrics. 1994;50:1064-1072.
26. Rossi R, Cioni E, Nuzzo A, Origliani G, Modena MG. Endothelial-dependent vasodilation and incidence of type 2 diabetes in a population of healthy postmenopausal women. Diabetes Care. 2005;28:702-707.
27. Tooke JE, Hannemann MM. Adverse endothelial function and the insulin resistance syndrome. J Intern Med. 2000;247:425-431.
28. Stehouwer CD, Lambert J, Donker AJ, van Hinsbergh VW. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res. 1997;34:55-68.
29. Jang Y, Lincoff AM, Plow ejectionfactor (EF), Topol EJ. Cell adhesion molecules in coronary artery disease. J Am Coll Cardiol. 1994;24:1591-1601.
30. Gearing AJ, Newman W. Circulating adhesion molecules in disease. Immunol Today. 1993;14:506-512.
31. Newman W, Beall LD, Carson CW, Hunder GG, Graben N, Randhawa ZI, Gopal TV, Wiener-Kronish J, Matthay MA. Soluble E-selectin is found in supernatants of activated endothelial cells and is elevated in the serum of patients with septic shock. J Immunol. 1993;150:644-654.
32. Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol. 1990;6:217-246.
33. Miles PD, Levisetti M, Reichart D, Khoursheed M, Moossa AR, Olefsky JM. Kinetics of insulin action in vivo. Identification of rate-limiting steps. Diabetes. 1995;44:947-953.
34. Vazquez LA, Pazos F, Berrazueta JR, Fernandez-Escalante C, Garcia-Unzueta MT, Freijanes J, Amado JA. Effects of changes in body weight and insulin resistance on inflammation and endothelial dysfunction in morbid obesity after bariatric surgery. J Clin Endocrinol Metab. 2005;90:316-322.
35. Hambrecht R, Adams V, Erbs S, Linke A, Krankel N, Shu Y, Baither Y, Gielen S, Thiele H, Gummert JF, Mohr FW, Schuler G. Regular physical activity improves endothelial function in patients with coronary artery disease by increasing phosphorylation of endothelial nitric oxide synthase. Circulation. 2003;107:3152-3158.
36. Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BH, Zinman B. Ramipril and the development of diabetes. JAMA. 2001;286:1882-1885.
37. Laufs U, Wassmann S, Hilgers S, Ribaudo N, Bohm M, Nickenig G. Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Am J Cardiol. 2001;88:1306-1307.
38. Hetzel J, Balletshofer B, Rittig K, Walcher D, Kratzer W, Hombach V, Haring HU, Koenig W, Marx N. Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler Thromb Vasc Biol. 2005;25:1804-1809.
39. Spieker LE, Sudano I, Hurlimann D, Lerch PG, Lang MG, Binggeli C, Corti R, Ruschitzka F, Luscher TF, Noll G. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation. 2002;105:1399-1402.
40. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290:2292-2300.